INSM — INSMED Inc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1104506 ·
Last close
$117.83
Market Cap
$25.73B
52W High
$212.75
52W Low
$90.39
ADV30
1,965,353
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 425,486,000 358,274,000 -101,308,000 -13,242,000 2,102,565,000 544,765,000 1,345,071,000
Mar 2026 305,964,000 258,544,000 -200,281,000 -163,563,000 2,075,863,000 582,188,000 1,371,011,000
Dec 2025 263,843,000 219,623,000 -249,708,000 -328,485,000 2,264,558,000 510,445,000 1,525,582,000
Sep 2025 142,342,000 112,977,000 -261,352,000 -370,021,000 2,360,736,000 334,764,000 1,415,165,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-895,664,000
Investing CF
$120,533,000
Financing CF
$954,589,000
CapEx
$-25,971,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.75
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-5,813,497,000
Inventory
$142,384,000
Receivables
$215,325,000
ST Investments
$615,547,000
EBIT TTM
$-793,299,000
Pretax Income TTM
$-869,106,000
Interest Exp TTM
$75,807,000
Analysts
22

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,137,634,944
EBITDA
$-794,955,008
Free Cash Flow
$-571,815,616
Enterprise Value
$27,840,161,792
Total Cash
$1,160,312,064
Total Debt
$739,724,032
Shares Out
218,381,503
Trailing EPS
$-4.12
Book Value
$3.47
ROE
-87.2%
ROA
-22.2%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 606,423,000 -994,776,000 -1,276,775,000 2,264,558,000 1,525,582,000 738,976,000 -935,014,000
Dec 2024 363,707,000 -786,570,000 -913,772,000 2,025,231,000 1,739,852,000 285,379,000 -683,882,000
Dec 2023 305,208,000 -680,929,000 -749,567,000 1,329,837,000 1,661,760,000 -331,923,000 -536,247,000
Dec 2022 245,358,000 -478,123,000 -481,534,000 1,656,435,000 1,568,484,000 87,951,000 -400,439,000

TTM Snapshot

Revenues TTM
$333,050,000
NetIncome TTM
$-767,185,000
OpCashFlow TTM
$0
Assets (Latest)
$2,264,558,000
Forward EPS
$0.74

Max Pain — expiry 2026-11-20

max pain strike: $115.00 · spot: $117.69 · call oi: 12,345 · put oi: 16,364
Expected Move to 2026-11-20: ±$19.60 (16.65%) — implied range $98.09 – $137.29 · ATM straddle on $120.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ROIV Roivant Sciences Ltd. $25.86B $35.80 —
RPRX Royalty Pharma plc $25.92B $58.21 —
ZTS Zoetis Inc. $29.36B $71.05 —
GMAB GENMAB A/S $21.72B $35.32 —
VTRS Viatris Inc $20.48B $17.83 —

News headlines (Yahoo Finance, 1h cache)

Did FDA Priority Review of ARIKAYCE ENCORE Data Just Shift Insmed's (INSM) Investment Narrative?
2026-09-21 18:18 · Yahoo
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
2026-09-21 11:00 · Yahoo
The Fund Exited Insmed (INSM) After the Investment Thesis Played Out
2026-09-16 14:40 · Yahoo
Insmed Expands Community Impact During Fifth Annual Global Day of Good
2026-09-16 11:00 · Yahoo
Exiting Insmed (INSM) Following Disappointing Key Drug Uptake
2026-09-10 11:52 · Yahoo
Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business
2026-09-02 08:42 · Yahoo
Insmed to Present at September 2026 Investor Conferences
2026-08-26 11:00 · Yahoo
BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
2026-08-24 11:00 · Yahoo
Insmed (INSM) Q2 2026 Earnings Call Transcript
2026-08-13 15:16 · Yahoo
What BioPharma Credit (BPCP) Said on Its H1 Earnings Call
2026-09-25 15:03 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.